Management and Preparedness for Infusion and Hypersensitivity Reactions
Abstract
Learning Objectives: After completing this course, the reader will be able to: Discuss the physiology of the different clinical hypersensitivity and infusion reactions to monoclonal antibodies and chemotherapy.Select appropriate prevention and treatment strategies for hypersensitivity reactions.Describe the differences between acquired and acute hypersensitivity reactions. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
For mAbs, hypersensitivity and infusion-related reactions are typically mild to moderate and occur predominantly during the first infusion.
“For mAbs, such reactions are typically mild to moderate and occur predominantly during the first infusion [77].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [77]
In clinical practice, one way to reduce the extent and rate of hypersensitivity and infusion-related reactions is to continue dosing at a slower intravenous infusion rate.
“In clinical practice, one way to reduce the extent and rate of hypersensitivity and IRRs is to continue dosing at a slower intravenous infusion rate [77, 78].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [77]
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574 · see citing works
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Echo, D. A. V., Hoff, D. D. V., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174 · see citing works
Albumin-bound paclitaxel: a next-generation taxane
Gradishar, W. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1041 · Cited by 706 · see citing works
The diagnosis and management of anaphylaxis: An updated practice parameter
Lieberman, P. L., KEMP, S., Oppenheimer, J., Lang, D. M., BERNSTEIN, I., Nicklas, R. A., Anderson, J. A., BERNSTEIN, D., BERNSTEIN, J., & Fink, J. N. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 664 · see citing works
The Incidence and Management of Infusion Reactions To Infliximab: A Large Center Experience
Cheifetz, A. S., Smedley, M. V., Martin, S., Reiter, M., Leone, G., Mayer, L., & Plevy, S. E. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07457.x · Cited by 491 · see citing works
Epidemiology of hypersensitivity drug reactions
Gomes, E. R., & Demoly, P. M. (2005) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/01.all.0000173785.81024.33 · Cited by 408 · see citing works
Clinical Features of Hypersensitivity Reactions to Carboplatin
Markman, M. M., KENNEDY, A. W., Webster, K. D., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1141 · Cited by 376 · see citing works
Rowinsky, E. K., Schwartz, G. H., Gollob, J., Thompson, J. A., Vogelzang, N. J., Figlin, R. A., Bukowski, R. M., Haas, N. B., Lockbaum, P., Li, Y.-P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.061 · Cited by 329 · see citing works
Markman, M. M., KENNEDY, A. W., Webster, K. D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.102 · Cited by 192 · see citing works
Prevention and Management of Antineoplastic-Induced Hypersensitivity Reactions
Zanotti, K. M., & Markman, M. M. (2001) · Drug Safety · doi:10.2165/00002018-200124100-00005 · Cited by 189 · see citing works
Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer
Cook‐Bruns, N. (2001) · Oncology · doi:10.1159/000055403 · Cited by 158 · see citing works
Dillman, R. O. (1999) · Cancer and Metastasis Reviews · doi:10.1023/a:1006341717398 · Cited by 155 · see citing works
THE DIAGNOSIS AND MANAGEMENT OF ANAPHYLAXIS
Ellis, A. K., & Day, J. H. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(18)30564-5 · Cited by 154 · see citing works
Feldweg, A. M., Lee, C.-W., Matulonis, U. A., & Castells, M. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.11.043 · Cited by 152 · see citing works
Polyzos, A., Tsavaris, N. B., Kosmas, C., et al. (2001) · Oncology · doi:10.1159/000055363 · Cited by 149 · see citing works
The diagnosis and management of anaphylaxis
Borchers, A. T., Naguwa, S. M., Keen, C. L., et al. (2004) · Comprehensive Therapy · doi:10.1007/s12019-004-0006-2 · Cited by 143 · see citing works
Hypersensitivity reactions related to oxaliplatin (OHP)
Brandi, G., Pantaleo, M. A., Galli, C., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601155 · Cited by 140 · see citing works
Successful re-treatment with taxol after major hypersensitivity reactions.
Peereboom, D. M., Donehower, R. C., Eisenhauer, E. A., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.5.885 · Cited by 111 · see citing works
Hypersensitivity and idiosyncratic reactions to oxaliplatin
Thomas, R. R., Quinn, M. G., Schüler, B., et al. (2003) · Cancer · doi:10.1002/cncr.11379 · Cited by 111 · see citing works
Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
Lenz, H. (2006) · PubMed · Cited by 91 · see citing works
Self-citationHypersensitivity Reactions to oxaliplatin: incidence and management.
Gowda, A. C., Goel, R., Berdzik, J., et al. (2004) · PubMed · Cited by 62 · see citing works
Non-allergic nature of docetaxel-induced acute hypersensitivity reactions
Ardavanis, A., Tryfonopoulos, D. J., Yiotis, I., Gerasimidis, G., Baziotis, N., & Rigatos, G. (2004) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000131685.06390.b7 · Cited by 55 · see citing works
Successful Desensitization to Oxaliplatin
Lydia, Fernando, N. H., Hurwitz, H. I., et al. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e532 · Cited by 37 · see citing works
Oxaliplatin-Associated Hypersensitivity Reactions: Clinical Presentation and Management
Hewitt, M. R., & Sun, W. (2006) · Clinical Colorectal Cancer · doi:10.3816/ccc.2006.n.027 · Cited by 21 · see citing works
Administration of Anti-EGFR Therapy: A Practical Review
Khoukaz, T. (2006) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2006.01.012 · Cited by 16 · see citing works
Cetuximab use without chronic antihistamine premedication
Timoney, J. P., Chung, K. Y., Park, V., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.13521 · Cited by 13 · see citing works
NAIRN, R., & HELBERT, M. (2007) · Elsevier eBooks · doi:10.1016/b978-0-323-04331-1.50031-0 · Cited by 9 · see citing works
A simplified premedication schedule for 1-hour paclitaxel administration.
Tsavaris, N. B., Kosmas, C., & Vadiaka, M. (2005) · PubMed · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Lecanemab: Appropriate Use Recommendations
Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., et al. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.30 · Cited by 961 · see citing works
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696 · see citing works
Szebeni, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.038 · Cited by 457 · see citing works
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447 · see citing works
Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy
Chung, C. H. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0012 · Cited by 278 · see citing works
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
Baldo, B. (2013) · OncoImmunology · doi:10.4161/onci.26333 · Cited by 191 · see citing works
Nakagawa, H., Iizuka, H., Nemoto, O., Shimabe, M., Furukawa, Y., Kikuta, N., & Ootaki, K. (2020) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2020.06.005 · Cited by 66 · see citing works
- Authors
- Lenz, H.-J.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Lenz, Heinz-Josef
- ORCID
- Lenz, Heinz-Josef
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-01
- Volume
- 12
- Issue
- 5
- Pages
- 601-609
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2106555579
- Cited by
- 479
- References
- 28
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 19 · 2023: 24 · 2022: 20 · 2021: 49 · 2020: 28 · 2019: 31 · 2018: 31 · 2017: 27 · 2016: 21 · 2015: 25 · 2014: 36 · 2013: 26 · 2012: 23
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- ImClone Systems, Inc.
- Topics
- Health Sciences › Medicine › Pharmacology › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- hypersensitivity, infusion reactions, monoclonal antibodies, chemotherapy, premedication, immediate hypersensitivity, delayed-type hypersensitivity, platinum complexes, taxanes, cetuximab, rituximab, trastuzumab, panitumumab, bevacizumab, carboplatin, oxaliplatin, paclitaxel, docetaxel, drug rechallenge
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Drug Hypersensitivity, Humans, Hypersensitivity, Delayed, Immunologic Factors, Infusions, Intravenous, Time Factors, Incidence, Platinum Compounds, Taxoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
